Alumis’ lupus drug heads to Phase III despite mid-stage miss

If Alumis' envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach the market. If envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach the market. Alumis will progress envudeucitinib to Phase III in SLE, despite the study miss across the general population. Credit: StanislavSukhin / Shutterstock.com. California-based biopharma company Alumis is taking its immunology candidate, envudeucitinib, to Phase III in a type of lupus, despite the drug missing its goals across the general population in a Phase IIb trial. During…

Source: Clinical Trials Arena